#1 Clinical Trials Search in Europe

Olodaterol

This article explores the use of Olodaterol, a long-acting beta2-agonist (LABA), in clinical trials for respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). The trials assess various aspects including efficacy, safety, dosage, and combination therapies to determine the optimal treatment approaches for patients with these respiratory disorders.

Table of Contents

What is Olodaterol?

Olodaterol, also known by its brand name Striverdi[1], is a medication used to treat chronic obstructive pulmonary disease (COPD). COPD is a group of lung diseases that cause breathing difficulties. Olodaterol belongs to a class of drugs called long-acting beta2-agonists (LABAs)[1]. It is designed to help patients breathe more easily by relaxing and opening the airways in the lungs.

How Olodaterol Works

Olodaterol works by binding to beta2-receptors in the smooth muscles of the airways. This action causes the muscles to relax, which in turn widens the airways, making it easier for patients to breathe. The effect of olodaterol is long-lasting, typically providing relief for up to 24 hours with a single dose[2].

Conditions Treated with Olodaterol

Olodaterol is primarily used to treat:

  • Chronic Obstructive Pulmonary Disease (COPD): This is the main condition for which olodaterol is prescribed. COPD is a group of lung diseases that includes emphysema and chronic bronchitis, characterized by airflow blockage and breathing-related problems[3].

It’s important to note that olodaterol is not approved for the treatment of asthma. In fact, using LABAs like olodaterol alone (without an inhaled corticosteroid) for asthma has been associated with an increased risk of asthma-related death[1].

How Olodaterol is Administered

Olodaterol is typically administered through an inhaler device called the Respimat. This device delivers the medication as a fine mist that patients inhale directly into their lungs. The usual dosage is two puffs once daily, at the same time each day[2]. It’s crucial for patients to be properly instructed on how to use the Respimat device to ensure they receive the full benefit of the medication.

Effectiveness of Olodaterol

Clinical trials have shown that olodaterol can significantly improve lung function in patients with COPD. Specifically, it has been found to:

  • Improve FEV1: FEV1 stands for Forced Expiratory Volume in one second, which is a measure of how much air a person can exhale in one second. Olodaterol has been shown to improve FEV1 in COPD patients[2].
  • Enhance exercise capacity: Studies have demonstrated that olodaterol can improve patients’ ability to exercise, which is an important factor in managing COPD[4].
  • Reduce lung hyperinflation: Olodaterol has been found to decrease lung hyperinflation, a condition where excess air becomes trapped in the lungs, making breathing difficult[4].

Olodaterol in Combination Therapy

Olodaterol is often used in combination with other COPD medications, particularly tiotropium. The combination of olodaterol and tiotropium (known as Tiotropium + Olodaterol) has shown to be more effective than either medication alone in improving lung function and quality of life for COPD patients[5]. This combination is available in a single inhaler, which can make it easier for patients to manage their medication regimen.

Potential Side Effects

Like all medications, olodaterol can cause side effects, although not everyone experiences them. Some potential side effects include:

  • Upper respiratory tract infection
  • Bronchitis
  • Urinary tract infection
  • Dizziness
  • Rash
  • Back pain
  • Joint pain
  • Increased heart rate

It’s important to discuss any side effects with your healthcare provider. They can help determine if the benefits of the medication outweigh the risks for your individual situation[3].

Patient Satisfaction and Quality of Life

Studies have shown that treatment with olodaterol, especially when combined with tiotropium, can lead to improvements in patients’ quality of life. This is often measured using questionnaires that assess factors such as breathlessness, activity levels, and overall health status. Many patients report feeling more satisfied with their treatment and experiencing improvements in their daily activities when using olodaterol[6].

In conclusion, olodaterol is an important medication in the management of COPD. While it can provide significant benefits in terms of lung function and quality of life, it’s crucial that patients use it as directed and under the supervision of a healthcare professional. Regular check-ups and open communication with your doctor are key to ensuring the best possible outcomes when using olodaterol.

Aspect Details
Study Types Randomized, double-blind, placebo-controlled, parallel group, and cross-over studies
Conditions Studied Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Primary Outcomes FEV1 AUC(0-3h), Trough FEV1, Inspiratory Capacity, Exercise Endurance Time
Secondary Outcomes FVC, SGRQ scores, TDI focal scores, various time-point FEV1 measurements
Dosages Tested Various, including 2 μg, 5 μg, 10 μg, and 20 μg
Combination Therapies Olodaterol + Tiotropium in fixed-dose combinations
Administration Method Inhalation via Respimat inhaler device
Study Durations Range from single-dose to 52-week treatments
Safety Assessments Adverse events, vital signs, ECG parameters, laboratory tests
Patient Populations Adults with asthma or COPD, including specific studies in Japanese patients

FAQ

  • What is Olodaterol and what is it used for? Olodaterol is a long-acting beta2-agonist (LABA) medication used to treat respiratory conditions such as chronic obstructive pulmonary disease (COPD). It works by relaxing and opening the airways in the lungs to make breathing easier.
  • How is Olodaterol administered in clinical trials? In clinical trials, Olodaterol is typically administered through inhalation using devices like the Respimat inhaler. It is often tested as a single agent or in combination with other medications such as tiotropium.
  • What are the primary outcomes measured in Olodaterol clinical trials? Primary outcomes often include measures of lung function such as Forced Expiratory Volume in one second (FEV1), inspiratory capacity, and endurance time during exercise tests. Safety assessments and quality of life measures are also commonly evaluated.
  • Are there any potential side effects of Olodaterol observed in clinical trials? While specific side effects are not detailed in the provided trial summaries, clinical trials typically monitor for adverse events related to cardiovascular effects, changes in blood chemistry, and other safety parameters. The safety profile is an important aspect of the drug's evaluation.
  • How does Olodaterol compare to other treatments in clinical trials? Clinical trials often compare Olodaterol to placebo or other active treatments, including combination therapies. These comparisons help determine the efficacy and safety of Olodaterol relative to existing treatments for respiratory conditions.

Ongoing Clinical Trials on Olodaterol

  • Study on the Effectiveness of Beclometasone, Glycopyrronium, and Formoterol in COPD Patients with Asthma Characteristics

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study Comparing Trelegy with LABA-LAMA Drug Combination for Improving COPD Control in High-Risk Patients

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • FEV1: Forced Expiratory Volume in one second, a measure of lung function that represents the volume of air a person can forcefully exhale in one second.
  • AUC: Area Under the Curve, a measure used to quantify the overall effect of a drug over time.
  • COPD: Chronic Obstructive Pulmonary Disease, a group of lung diseases that cause airflow blockage and breathing-related problems.
  • Respimat: A type of inhaler device used to deliver respiratory medications in a fine mist form.
  • Tiotropium: A long-acting anticholinergic bronchodilator medication often used in combination with Olodaterol for COPD treatment.
  • FVC: Forced Vital Capacity, the total amount of air exhaled during a forced expiratory volume test.
  • SGRQ: Saint George's Respiratory Questionnaire, a standardized measure of health status for patients with airflow obstruction diseases.
  • TDI: Transitional Dyspnoea Index, a measure used to evaluate changes in breathlessness in patients with respiratory diseases.
  • Trough FEV1: The FEV1 measured at the end of a dosing interval, typically used to assess the duration of action of a medication.
  • Bronchoprotection: The ability of a medication to protect against bronchoconstriction or narrowing of the airways.

References

  1. https://clinicaltrials.gov/study/NCT03030638
  2. https://clinicaltrials.gov/study/NCT01431287
  3. https://clinicaltrials.gov/study/NCT01536262
  4. https://clinicaltrials.gov/study/NCT01533935
  5. https://clinicaltrials.gov/study/NCT01431274
  6. https://clinicaltrials.gov/study/NCT02173769